Dow Up0.07% Nasdaq Up0.61%

Sucampo Pharmaceuticals, Inc. (SCMP)

-NasdaqGM
11.93 Up 0.08(0.68%) 4:00PM EST
ProfileGet Profile for:
Sucampo Pharmaceuticals, Inc.
4520 East-West Highway
3rd Floor
Bethesda, MD 20814
United States - Map
Phone: 301-961-3400
Fax: 301-961-3440
Website: http://www.sucampo.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:77

Business Summary 

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other drug technologies in the Americas, Europe, and Asia. It is developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, as well as for other therapeutic applications. The company, through its collaboration and license agreement with Takeda Pharmaceutical Co., Ltd., offers AMITIZA in the United States for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; and opioid-induced constipation in adults with chronic non-cancer pain. It also provides AMITIZA in Japan through its collaboration and license agreement with Abbott Japan Co., Ltd., for chronic constipation in adults; and in the United Kingdom and Switzerland for the treatment of chronic idiopathic constipation. In addition, the company markets RESCULA in the United States for the treatment of open-angle glaucoma and ocular hypertension. Its pipeline also includes AMITIZA, which is in Phase III trial for pediatric functional constipation. The company’s other pipeline products consist of IV Ion Channel Activator, which is in Phase IIa clinical trial for the treatment of Lumbar spinal stenosis; PO Ion Channel Activator that is in Phase Ia trial for the treatment of Lumbar spinal stenosis; and cobiprostone, which has completed Phase I clinical development for the treatment of oral mucositis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Bethesda, Maryland.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Sucampo Pharmaceuticals, Inc.

Corporate Governance 
Sucampo Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 3. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 7; Compensation: 2.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Ryuji Ueno M.D., Ph.D., Ph.D., 60
Co-Founder, Chairman Emeritus and Scientific Advisor
865.00K0.00
Mr. Andrew P. Smith , 51
Principal Accounting Officer
405.00K192.00K
Mr. Thomas J. Knapp J.D., 61
Chief Legal Officer, Exec. VP and Corp. Sec.
467.00K0.00
Mr. Stanley G. Miele , 50
Sr. VP of Sales & Marketing and Pres of Sucampo Pharma Americas LLC
350.00K477.00K
Mr. Peter S. Greenleaf , 44
Chief Exec. Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders